Abstract:Background: Serotonin/5-HT antagonist and reuptake inhibitors (SARIs) ameliorate depression by increasing the terminal 5-HT through the activation of somatodendritic 5-HT1A autoreceptors. In addition to their therapeutic application as standalone antidepressants, they are co-administered with selective serotonin reuptake inhibitors (SSRI) to improve unpleasant side effects associated with SSRI-treated depression. However, only a few of the atypical antidepressants are available and not without some serious aftereffects. This study aims at the identification of novel promising SARIs using computational chemistry and high throughput screening. Methods: Pharmacophore features were modelled using LigandScout 4.3 and validated through the area under curve (AUC), enrichment factor (EF) and Guner-Henry (GH) scores. Molecular docking was employed for virtual screening against modelled human 5HT1A homology receptor, molecular dynamics simulations and ADMET predictions. Results: The adopted pharmacophore possesses AUC, EF and GH scores of 0.7, 30.9 and 0.6 respectively, thus validated and used for molecular database screening. The modelled 5-HT1A homology receptor, validated using RCSB structure validation protocols, was employed for molecular docking and dynamics simulations. From the IBScreen database, the ligands, STOCK6S-36853, STOCK7S-36094, STOCK3S-94557, STOCK7S-28769 and STOCK5S-36248 interacted more strongly against the 5-HT1A receptor with docking scores of -8.735, -8.677, -8.140, -7.911 and -7.710 kcal/mol, and binding free energy of -29.72, -38.87, -29.85, -7.65 and -34.71 kcal/mol respectively, compared to fluoxetine and trazodone (positive controls) while albendazole and metformin (negative controls) scored least. They demonstrated good stability, satisfy the BDDCS RO5 and thus, are identified as potent SARIs. Conclusion: The study represents a cost-effective, faster and environmentally friendly approach to the discovery of promising SARI antidepressants for further translational study.

Design, synthesis, and biological evaluation of aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT1A/5-HT7

Design, synthesis, and biological evaluation of piperazine derivatives involved in the 5-HT1AR/BDNF/PKA pathway

Design, Synthesis, and Structure-Activity Relationship Studies of Novel Indolyalkylpiperazine Derivatives as Selective 5-HT1A Receptor Agonists

Molecular Modelling and Virtual Screening to Identify New Piperazine Derivatives as Potent Human 5-HT1A Antagonists and Reuptake Inhibitors

Synthesis and biological evaluation of multimodal monoaminergic arylpiperazine derivatives with potential antidepressant profile

Pharmaceutical Studies on Piperazine-Based Compounds Targeting Serotonin Receptors and Serotonin Reuptake Transporters

Design, synthesis and biological evaluation of arylpropylamine derivatives as potential multi-target antidepressants

Discovery of Novel Indolealkylpiperazine Derivatives As Potent 5-HT1A Receptor Agonists for the Potential Future Treatment of Depression

Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity

Synthesis and biological evaluation of novel isobenzofuran-1(3H)-one derivatives as antidepressant agents

Exploration of 1-(4-(7-Azaindole)-3,6-dihydropyridin-1-yl)alkyl-3-(1H-indol-3-yl)pyrrolidine-2,5-dione Derivatives with Affinity for the Serotonin Transporter

Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.

Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics

Design, Synthesis and Biological Activities of Piperidine-Spirooxadiazole Derivatives As Α7 Nicotinic Receptor Antagonists

Discovery of Aryl-Piperidine Derivatives As Potential Antipsychotic Agents Using Molecular Hybridization Strategy.

Development of heterocyclic-based frameworks as potential scaffold of 5-HT1A receptor agonist and future perspectives: A review

Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.

Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression.

Molecular Modeling of the 3D Structure of 5-HT(1A)R: Discovery of Novel 5-HT(1A)R Agonists Via Dynamic Pharmacophore-Based Virtual Screening.

Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-Carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor.

Synthesis and Pharmacological Characterization of Novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides As Potential Multireceptor Atypical Antipsychotics